Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + Dexamethasone in newly diagnosed Primary Immune Thrombocytopenia
NCT07559331Phase 3Recruiting
- Sponsor
- Shandong University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in primary immune thrombocytopenia (ITP), sponsored by Shandong University. Started Apr 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07559331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559331.